Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice

Reviews in Urology

Vladimir Mouraviev¹  Dimitrios Telonis¹  David Albala¹  Christopher M Pieczonka¹ 

[1] Associated Medical Professionals,, Syracuse, NY

关键词: Metastatic castrate-resistant prostate cancer;    Immunotherapy;    Sipuleucel-T;    Clinical practice;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Sipuleucel-T treatment is associated with a significant and consistent survival benefit in patients with metastatic castrate-resistant prostate cancer. Most adverse events are infusion related, manageable, and of short duration. Early screening and diagnosis of metastatic disease is important, as the greatest survival benefit may occur in patients with a lower disease burden. The short duration of sipuleucel-T treatment facilitates the use of subsequent therapies. Sipuleucel-T is now being used in the clinic for patients with a lower disease burden. We present our own experience with the use of sipuleucel-T in the setting of a large urology practice.

【 授权许可】

Unknown